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Activation of p53 by scaffold-stabilised expression of Mdm2-
binding peptides: visualisation of reporter gene induction at
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Small peptides that perturb intracellular signalling pathways are useful tools in the identification and validation of new drug targets. To
facilitate the analysis of biologically active peptides, we have developed retroviral vectors expressing an intracellular scaffold protein
that significantly enhances the stability of small peptides in mammalian cells. This approach was chosen because retroviral transduction
results in efficient and controlled delivery of the gene encoding the effector peptide, while the scaffold protein not only stabilises the
peptide but also facilitates the analysis and potential isolation of the target protein. Here, we have adapted a p53-responsive reporter
assay to flow cytometry to demonstrate the versatility of this approach by using peptides with known Mdm2-binding activities
inserted into a stable scaffold protein that is suitable for intracellular expression in multiple compartments of mammalian cells. This
strategy should be generally applicable to the study of small biologically active peptides in diverse functional assays.
British Journal of Cancer (2004) 91, 1488–1494. doi:10.1038/sj.bjc.6602143 www.bjcancer.com
Published online 21 September 2004
& 2004 Cancer Research UK
Keywords: peptides; scaffold protein; retroviral vector; p53 activity
                                     
The use of cellular assays to analyse the biological activities of
short peptides is a powerful approach for validating peptide
modulators of signalling pathways and for mapping functional
protein domains (Bottger et al, 1996, 1997; Souroujon and Mochly-
Rosen, 1998). Characterisation of peptides derived from natural
protein sequences, or retrieved from the screening of random
peptide libraries, can be used to identify agonists or antagonists of
therapeutic relevance. However, the technical limitations asso-
ciated with analyses of peptides can be significant, both due to the
poor half-life of short peptides in the intracellular milieu of
mammalian cells and because transfer of most peptides across
cellular membranes is inefficient. Small protein scaffolds have been
widely used in the screening of random peptide libraries by phage
display (Ladner, 1995; Nygren and Uhlen, 1997; Zwick et al, 1998).
In contrast, there are only few reports on scaffolds suitable for
intracellular peptide display in mammalian cells (Bottger et al,
1997; Abedi et al, 1998; Gururaja et al, 2000; Hitoshi et al, 2003).
In this study, we have used retroviral vectors to achieve efficient
delivery of effector molecules into mammalian cells and we
engineered peptides with known p53-inducing activities into a
small stable scaffold protein, chymotrypsin inhibitor 2 (CI2), a
protease inhibitor naturally present in the seeds of barley
(McPhalen and James, 1987). Previous studies have shown that
the active loop structure of CI2 can be modified by insertions,
deletions and amino-acid substitutions, without the overall
stability of the protein being affected (Osmark et al, 1993).
Moreover, CI2 does not contain any disulphide bonds, thus
making it a suitable scaffold protein for expression in any
subcellular compartment in mammalian cells. Two p53-activating
peptides were used in this study, 12.1 and Arf37. Both peptides
bind Mdm2, an E3 ubiquitin ligase responsible for the rapid
degradation of p53 observed in unchallenged healthy cells (Honda
et al, 1997). The 12.1 peptide was identified in a phage display
screen for Mdm2-binding peptides (Bottger et al, 1996), while the
Arf37 peptide is derived from the N-terminal end of the mouse
p19
ARF protein (Weber et al, 2000). Mdm2 is an attractive drug
target (Bottger et al, 1997; Zheleva et al, 2003; Vassilev et al, 2004)
and these peptides serve to illustrate this. By comparing the
activity of 12.1 and Arf37 expressed as free peptides (uncon-
strained) or presented by CI2 (constrained), we show that scaffold-
mediated stabilisation significantly enhances the activity of small
peptides. To our knowledge, such direct comparative data have not
been reported previously. We propose that scaffold-aided peptide
presentation combined with retroviral transduction has broad
applications for the validation of biologically active peptides and
for the elucidation of intracellular signalling pathways in
mammalian cells.
MATERIALS AND METHODS
Cells
The T22 reporter cells are stably transfected with a p53-responsive
reporter construct, pRGCd-Fos-lacZ, as described elsewhere
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y(Hupp et al, 1995; Bottger et al, 1997). The T22 cells were cultured
in DMEM containing 10% newborn calf serum. The Bosc23
packaging cells, the anti-human NGFR hybridoma (HB-8737)
(ATCC) and U2-OS cells were cultured in DMEM containing 10%
foetal calf serum.
Genetic constructs
The ncmDNGFR bicistronic retroviral vector is derived from the
CMVbipep vector (Duch et al, 1999), in which the neomycin
resistance gene present downstream of the internal ribosomal
entry site (IRES) element has been exchanged for a truncated form
of the human nerve growth factor receptor, DNGFR (Mavilio et al,
1994). For structurally constrained presentation of peptides, a 64
amino-acid version of CI2 was employed as a scaffold protein
(McPhalen and James, 1987). CI2 was inserted into ncmDNGFR
upstream of the IRES element to generate ncmDNGFR-CI2 and
ncmDNGFR-nuclear localisation signal (NLS)-CI2; the latter
contains the NLS of SV40 T antigen placed N-terminally in frame
with CI2. Peptides were inserted into CI2 by replacing the sequence
corresponding to the six natural amino acids in the active site loop
of CI2 (IVTMEY) with the sequence encoding the relevant
heterologous peptide sequences (12.1, 12.1-Ala, Arf15, Arf37).
Sequences encoding unconstrained peptides were inserted directly
upstream of the IRES element in ncmDNGFR. As a positive control
in the p53 reporter assay, the gene encoding full-length human
p14
ARF was inserted into the ncmDNGFR to generate ncmDNGFR-
huARF.
Cytological techniques
Cell populations were stained for the DNGFR transduction marker
using the anti-NGFR mAb, followed by an RPE conjugated
secondary antibody (goat anti-mouse F(ab)2-RPE, DAKO). p53-
dependent b-gal activity induced by the different effector peptides
was measured by loading the cells with a substrate for b-gal,
fluorescein di-b-D-galactopyranoside (FDG, SIGMA), which is
cleaved in b-gal-positive cells to yield fluorescein (Nolan et al,
1988). Cell cycle analysis was performed by gentle ethanol fixation,
RNAse treatment and propidium iodide (PI) staining (50mgml
 1
PI in PBS for 1h at room temperature (RT)). Data were acquired
using a FACS Vantage flow cytometer.
Transfections
U2-OS cells were plated in 10cm dishes and grown to 90%
confluency. Cells were transfected using Lipofectaminet 2000
(Invitrogen) with 5–20mg plasmid DNA per dish and incubated
for an additional 24h. MG132 (10mM final concentration) was
added for the final 4h of incubation.
Cell lysis and immunoprecipitations
Cells from each 10cm dish were lysed on ice in 700ml NP-40 lysis
buffer (50mM Hepes (pH 7.5), 100mM NaCl, 5mM EDTA, 0.5%
NP-40) containing protease inhibitor cocktail Completet (Roche
Diagnostics). The protein concentration of lysates was determined
using a BCAt Protein Assay Kit (Pierce) and lysate volumes
adjusted to give equivalent total protein concentrations. In all,
650ml of each adjusted lysate (in NP-40 lysis bufferþ1m M DTT)
was mixed with 20ml protein G Sepharose coupled to the 4B2
antibody (Chen et al, 1993) and incubated, with constant rotation,
for 1h at 41C. Immunoprecipitates were washed 4  in NP-40 lysis
bufferþ1m M DTT and eluted in 60ml NP-40 lysis bufferþ100mM
DTT.
Gel electrophoresis and Western blotting
Samples were run on 4–12% Bis–Tris gels in MES running buffer
(Novex) and transferred to nitrocellulose overnight at 15mA.
Membranes were blocked for 2h in PBSþ0.1% Tween
(PBST)þ5% nonfat milk. Primary antibodies 4B2, DO-1 (Bartek
et al, 1993; Stephen et al, 1995), a-CI2A, or a-Arf (both polyclonal
rabbit antisera) were incubated for 1h at RT. Blots were washed
4  with PBST and incubated with a-mouse-HRP or a-rabbit-HRP
(Jackson) for 45min at RT and then washed 4  with PBST and
1  with PBS. The signal was generated with ECL (Amersham
Biosciences) or Dura (Pierce) substrate and exposed to a film.
Immunofluorescence
U2-OS cells were seeded at a density of 2.5 10
5cellsml
 1 in two-
well permanox chamber slides and transiently transfected with
plasmid DNA encoding human Mdm2, the CI2 scaffold proteins, or
full-length human Arf, using Lipofectamine as described above. At
24h post-transfection, the cells were fixed and permeabilised for
8min in ice-cold methanol/acetone 50%/50% (vv
 1), blocked for
40min at RT with 0.1% (wv
 1) BSA in PBS and incubated for 1h at
RT with primary antibodies diluted in DMEM, 10% (vv
 1) FCS.
(a-CI2 polyclonal antibody and 4B2 ascites were diluted 1:100
each, a-Arf polyclonal antibody was diluted 1:1000.) Following
incubation with secondary antibodies (30min, RT), FITC-con-
jugated anti-mouse IgG (1:80) and TRITC-conjugated anti-rabbit
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Figure 1 Design of retroviral vectors used for peptide expression. All
vectors contain a chimeric 50 LTR. Transcription in transfected cells is driven
by the cytomegalovirus (CMV) promoter and in transduced cells by the
retroviral LTR. An IRES element facilitates CAP-independent translation of
the DNGFR transduction marker. The ncmDNGFR vector (A) was used
for expression of unconstrained peptides and full-length proteins, while the
ncmDNGFR-CI2 (B) and the ncmDNGFR-NLS-CI2 (C) vectors were used
for expression of constrained peptides.
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yIgG (1:400), the cells were washed extensively in PBS, fixed in
Dapi, mounted with Hydromount and visualised by microscopy on
a Nikon Eclipse E600 microscope.
RESULTS
Design of the retroviral vector
Bicistronic retroviral vectors based on the murine Akv retrovirus
were used for efficient transduction of mammalian cells (Duch
et al, 1999). The ncmDNGFR vector was used for the expression
of unconstrained peptides and full-length control proteins
(Figure 1A), while structurally constrained peptides were ex-
pressed from the ncmDNGFR-CI2 (Figure 1B) or from
ncmDNGFR-NLS-CI2 (Figure 1C). Long-term overexpression of
CI2 in mammalian cells did not result in cellular toxicity (A Jensen
et al, unpublished).
CI2 presentation of an Mdm2-binding peptide:
visualisation of reporter gene induction at the single-cell
level
Examples of the data obtained in the flow cytometry-based
p53 reporter assay are shown as density plots in Figure 2. A
marked increase in p53-driven b-gal activity was observed in
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Figure 2 Visualisation of p53 activity at the single-cell level. T22 cells were analysed 68h after transduction by staining for DNGFR (y-axis) and by assaying
for b-gal activity (x-axis). Density plots from representative experiments for each vector are shown: (A) ncmDNGFR-CI2-12.1-Ala; (B) ncmDNGFR-CI2-
12.1; (C) ncmDNGFR-NLS-CI2-12.1-Ala; (D) ncmDNGFR-NLS-CI2-12.1; (E) ncmDNGFR-huArf and (F) and ncmDNGFR-CI2.
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(Figure 2B and D), compared to cultures expressing the
CI2-presented 12.1-Ala control peptide (Figure 2A and C). The
addition of an NLS to the CI2-12.1 protein further increased
the number of b-gal-positive cells in the culture (Figure 2B and D).
When the expression levels of CI2-12.1 and CI2-12.1-Ala were
analysed by Western blot, the two proteins were expressed to equal
levels (data not shown). Thus, the difference in reporter gene
expression can be ascribed to a difference in biological activity
between these proteins. Further, all cells transduced with
ncmDNGFR-huARF were positive for p53-driven b-gal activity
(Figure 2E) and expression of p53-activating molecules resulted in
a lower overall proportion of transduced cells at 68h after
transduction (Figure 2B, D and E), indicating that the growth rate
of cells transduced with p53-activating molecules was slowed. This
was particularly pronounced for cultures transduced with
ncmDNGFR-huARF, in which less than 10% of the total population
was NGFR positive at this time point. These results did not reflect
lower transduction efficiencies of the three cultures expressing
p53-inducing molecules, since analyses performed at an earlier
time point after transduction showed similar proportions of
NGFR-positive cells in all cultures (not shown).
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Figure 3 The 12.1 and the Arf37 peptides are stabilised by the CI2
scaffold. T22 reporter cells were transduced with a panel of retroviral
vectors expressing the 12.1 peptide and appropriate controls: (A)
ncmDNGFR, ncmDNGFR-12.1, ncmDNGFR-12.1-Ala, ncmDNGFR-CI2-
12.1, ncmDNGFR-CI2-12.1-Ala, ncmDNGFR-NLS-CI2-12.1 and
ncmDNGFR-NLS-CI2-12.1-Ala, (B) ncmDNGFR-Arf37, ncmDNGFR-CI2,
ncmDNGFR-CI2-Arf37, ncmDNGFR-NLS-CI2, ncmDNGFR-NLS-CI2-
Arf37, ncmDNGFR-NLS-CI2-Arf15 and ncmDNGFR-huArf. Samples were
analysed 68h after transduction by staining the cells for DNGFR and
assaying for b-gal activity. Data are plotted as the percentage of double-
positive cells (DNGFR and b-gal) of the total transduced population
(DNGFR-positive cells). Results from three independent transductions are
shown.
-Mdm2
-CI2
-Arf
CI2-Arf37
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-Mdm2
-p53
A
B
Figure 4 Co-precipitation of CI2-Arf37 and endogenous Mdm2 (A).
Whole-cell lysates of U2-OS cells transfected with ncmDNGFR-CI2 or
ncmDNGFR-NLS-CI2-Arf37 were analysed by Western blot using
antibodies against p53, Mdm2 or CI2 (B). Whole-cell lysates of U2-OS
cells transfected with ncmDNGFR-CI2, ncmDNGFR-NLS-CI2-Arf37 or
human Arf were precipitated with protein G sepharose-coupled a-Mdm2.
The bound material was eluted and analysed by Western blot using
antibodies against Mdm2, CI2 and Arf.
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Mdm2-binding peptides
Having established that CI2 is a functional intracellular scaffold
protein for presentation of the 12.1 peptide, we wished to
determine if this was more broadly applicable to other peptides
and we therefore inserted a different Mdm2-binding peptide into
CI2, namely a 37 amino-acid large peptide from the N-terminus of
p19
ARF, Arf37. In the same experiment, we also assayed the
biological activity of the unconstrained 12.1 and Arf37 peptides
expressed from the retroviral vector and determined if the addition
of a nuclear targeting signal enhanced the activity of the CI2-
presented peptides. When the 12.1 peptide was expressed as a free
peptide, no activity over background levels was observed, while
CI2-constrained 12.1 peptide activated p53 in approximately 25%
of the transduced population (Figure 3A). The addition of
stabilising residues to the N- and C-termini of the unconstrained
12mer peptide (MG-12.1-GGPP) did not result in any detectable
increase in activity (data not shown). Targeting CI2 to the nucleus
increased the proportion of p53-activated cells to approximately
50% of the total transduced population, likely reflecting an
increased nuclear concentration of CI2-12.1 (Figure 3A). All
12.1-Ala control constructs showed background levels of activity,
confirming the peptide-specific p53 induction.
CI2 presentation also enhanced the activity of the Arf37 peptide
(Figure 3B), demonstrating that it can improve the stability of
quite sizeable peptides. As for the 12.1 peptide, the addition of
stabilising residues flanking the free Arf37 peptide (MG-Arf37-
GGPP) did not improve the activity of the unconstrained Arf37
peptide (data not shown). We ascribe the lack of activity in cells
transduced with vectors expressing free (unconstrained) 12.1 and
Arf37 to poor stability rather than poor expression of the peptides,
since previous studies using another functional assay have shown
that short peptides are expressed from this position in the vector
(Tolstrup et al, 2001). In contrast to the 12.1 peptide, targeting the
scaffold to the nucleus did not increase the activity of CI2-Arf37,
likely because the Arf37 peptide already contains a sequence of
basic residues that confer nuclear localisation. A vector expressing
CI2 presenting amino acids 1–15 of p19
ARF was also included in
the assay, ncmDNGFR-NLS-CI2-Arf15. This 15mer peptide has
been shown to bind Mdm2, but to lack other determinants
necessary for p53 induction. In agreement with this, we detected no
activity over background levels in cultures transduced with
ncmDNGFR-NLS-CI2-Arf15 peptide. Retroviral delivery of full-
length human p14
ARF resulted in near 100% reporter assay-positive
cells in the transduced population, suggesting that this level of
p53-inducing activity represents near saturation in the assay.
Binding and co-localisation of CI2-Arf37 with endogenous
Mdm2
To obtain evidence that the p53-inducing activity of the scaffold-
presented peptides resulted from an interaction between the CI2-
presented peptides with endogenous Mdm2, co-precipitation
experiments were performed. In these experiments CI2-Arf37
was used, since this protein activated p53 potently in the flow
cytometry-based assay. First, the expression levels of endogenous
Mdm2 and p53 were analysed in CI2- and CI2-Arf37-transfected
U2-OS cells (Figure 4A). In agreement with our previous results
from the reporter assay, we found that the level of p53 protein was
increased in CI2-Arf37-expressing cells compared to that in cells
expressing the empty scaffold protein. Thus, upregulation of p53
was detectable also at the protein level. This experiment also
showed that endogenous Mdm2, as well as transfected CI2 and
CI2-Arf, were readily detected. We then analysed the ability of
endogenous Mdm2 to co-precipitate CI2, CI2-Arf37 and human
Arf by running Mdm2-immunoprecipitated material on a gel and
performing Western blot analysis with a-CI2 and a-Mdm2
antibodies (Figure 4B). We observed a clear co-precipitation of
CI2-Arf37 and human Arf with Mdm2, while the empty CI2
scaffold did not co-precipitate. These data confirm that CI2-
presented Arf37 interacts specifically with endogenous Mdm2.
To demonstrate that an interaction between CI2-Arf37 and
Mdm2 occurs also in intact cells, we analysed CI2- and CI2-Arf37-
expressing cells by immunofluorescence (Figure 5). This experi-
ment demonstrates that Mdm2 localises to the nucleus and in
particular to the nucleoli. A clear co-localisation with Mdm2 of
-CI2 -Mdm2
-Arf -Mdm2
Merged Dapi
huArf
CI2-Arf37
CI2
Merged Dapi
Figure 5 Co-localisation of CI2-Arf37 and Mdm2. U2-OS cells transfected with human Mdm2 and ncmDNGFR-CI2 (upper row), ncmDNGFR-NLS-CI2-
Arf37 (middle row) or human Arf (lower row) were analysed by immunofluorescence using antibodies against Mdm2 (first column), CI2 or Arf (second
column) and by merging the images (third column). The column furthest to the right shows the cell nucleus stained with Dapi.
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scaffold was distributed in both the cytosol and the nucleus, with
no accumulation in the nucleoli. To obtain a clear signal, the data
shown in Figure 5 are from cells transiently transfected with
human Mdm2; however, a similar co-localisation was also
observed when CI2-transfected cells were stained for endogenous
Mdm2 (not shown). These results firmly establish the co-
localisation of CI2-Arf37 with Mdm2.
Cell cycle arrest induced by the scaffold-presented 12.1
peptide
To confirm that biologically relevant activities are measured in the
p53 reporter assay, we performed cell cycle analyses by determin-
ing the DNA content in T22 cells transduced with ncmDNGFR-
CI2-12.1 and control vectors. Again, we used the DNGFR surface
marker to distinguish the transduced population from the
untransduced in order to take into account the growth disadvan-
tage of cells expressing p53-activating peptides. The results
demonstrate that expression of CI2-presented 12.1 reduced the
percentage of cells progressing through S phase (Figure 6B)
compared to that in control cultures (Figure 6A and C). Similar
results were obtained using CI2-Arf37 (not shown).
DISCUSSION
In this study, we have combined the use of retroviral transduction
methods and scaffold-mediated peptide presentation to circum-
vent two key limitations associated with the analysis of short
peptides inside cells, namely peptide delivery and peptide stability.
When using low multiplicities of infection, retroviral transduction
results in the delivery of a controlled copy number of the sequence
encoding the effector molecule. We found that CI2-stabilised
Mdm2-binding peptides induced a potent p53 response, which was
readily detected in a flow cytometry-adapted p53-reporter assay.
The same peptides did not stimulate a detectable response when
expressed as free peptides, likely due to the poor stability of small
peptides in mammalian cells, Moreover, we show that CI2-Arf37, a
molecule that exhibits potent activity in the flow cytometry-based
p53 reporter assay, specifically interacts and co-localises with
endogenous Mdm2. These data suggest that CI2 is a versatile
scaffold protein, which will prove useful for validation studies and
for the presentation of intracellular combinatorial peptide libraries
used in functional screens.
Related strategies have been used to identify active peptides
from random libraries (Peelle et al, 2001; Xu et al, 2001; Hitoshi
et al, 2003) and the vectors presented here could be similarly
applied. Finally, by monitoring the total cell population in a flow
cytometry-based assay, our data show that cells expressing p53-
activating peptides rapidly become outgrown by the untransduced
cells in the culture. These results underscore the importance of
performing analysis at the single-cell level when studying peptides
with growth-inhibitory properties, since cells that express potent
effector molecules selectively get depleted from the total cell
population.
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Figure 6 Cells expressing the CI2-presented 12.1 peptide show slowed
cell cycle progression. T22 cells transduced with (A) ncmDNGFR; (B)
ncmDNGFR-NLS-CI2-12.1 and (C) ncmDNGFR-NLS-CI2-12.1-Ala were
stained for DNGFR and for DNA content at 68h after transduction. A
representative experiment is shown.
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